We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Medications for Alzheimer's disease: Benefits of currently approved drugs are limited, but research continues.
- Abstract
The article discusses the treatment of Alzheimer's disease which is expected to contract 7.7 million people in 2030. It notes that cholinesterase inhibitors have improved the cognitive function of patients with mild to moderate Alzheimer's. It mentions that glutamatic acid, which can be toxic to nerve cells, is blocked by the N-methyl-D-aspartate (NMDA) of memantine.
- Subjects
AMANTADINE; ANTIDEPRESSANTS; TRANQUILIZING drugs; NEUROPROTECTIVE agents; ALZHEIMER'S disease; CHOLINESTERASE inhibitors; COGNITION; ENZYME inhibitors; MEMORY; HEALTH outcome assessment; BEHAVIOR disorders; TREATMENT effectiveness; THERAPEUTICS
- Publication
Harvard Mental Health Letter, 2011, Vol 27, Issue 10, p4
- ISSN
1057-5022
- Publication type
Article